AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer
AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer
aim immunotech宣佈羅斯韋爾公園研究關於早期三陰性乳腺癌中阿米芬使用的1期數據在《癌症免疫療法雜誌》上發表
AIM ImmunoTech Announces Publication Of Phase 1 Data From Roswell Park Study On Ampligen In Early-Stage Triple-Negative Breast Cancer In The Journal For ImmunoTherapy Of Cancer
aim immunotech宣佈羅斯韋爾公園研究關於早期三陰性乳腺癌中阿米芬使用的1期數據在《癌症免疫療法雜誌》上發表
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間